Numerous neurodegenerative diseases are characterized by the accumulation of tau aggregates. Targeting tau oligomers can lead to the development of effective treatments for these diseases.
|Alzheimer’s disease||Hallervorden-Spatz disease|
|Amyotrophic lateral sclerosis/parkinsonism-dementia complexa||Myotonic dystrophy|
|Argyrophilic grain dementiaa||Niemann-Pick disease, type C|
|Chronic Traumatic Encephalopathya (traumatic brain injury)||Non-Guamanian motor neuron disease with neurofibrillary tangles|
|Creutzfeldt-Jakob disease||Pick’s diseasea|
|Corticobasal degenerationa||Postencephalitic parkinsonism|
|Diffuse neurofibrillary tangles with calcificationa||Prion protein cerebral amyloid angiopathy|
|Down’s syndrome||Progressive subcortical gliosisa|
|Frontotemporal dementia with parkinsonism linked to chromosome 17a||Progressive supranuclear palsya|
|Gerstmann-Sträussler-Scheinker disease||Subacute sclerosing panencephalitis|
aDiseases in which tau-positive neurofibrillary pathology is the most predominant neuropathologic feature. Lee et al., Annu. Rev. Neurosci. 2001, 24:1121.